Through this nano-selenium–peptide platform, we demonstrate effective intracellular checkpoint modulation that achieves superior therapeutic efficacy compared to conventional PD-L1 monoclonal antibodies, offering a promising and innovative approach to advance the next generation of cancer immunotherapies, particularly for checkpoint inhibitor-refractory tumors. This evidence concerns the gene CD274 and cancer.